How do you approach hypogammaglobulinemia monitoring when using obinutuzumab for refractory nonrenal SLE patients?
Furie et al., PMID 41789864
Does their other immunosuppressive medication regimen influence your approach at all?
1 Answer
Mednet MemberInvited Expert
Nephrology · Johns Hopkins University
Answered on
I would start with a baseline evaluation that includes quantitative IgG levels, HBV serologies, including HBsAg and anti-HBc, to assess reactivation risk even if HBsAg-negative, and a CBC with differential. Before treatment, I would make sure all non-live vaccines are completed, and I would avoid li...
Join for free or sign in to see the full answer